Affinergy teams with Synthes
This article was originally published in The Gray Sheet
"Biological glue" proprietor Affinergy and orthopedic device manker Synthes will collaborate on multiple product applications across the spine, trauma and craniomaxillofacial markets under a long-term development program announced Sept. 11. Affinergy's Interfacial Biomaterial coating process can reduce the risks of infection, friction and clotting associated with an orthopedic implant, and "provide for a much tighter integration of the actual device," the company says (1"The Gray Sheet" March 8, 2004, p. 26). The firm is interested in targeting the cardiovascular market as well...
You may also be interested in...
Affinergy's plan to license its Interfacial Biomaterial (IFBM) coating process will allow the start-up to avoid the costs of bringing a combination product to market
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.